Corcept Therapeutics (NASDAQ:CORT) Stock Price Down 18% – What’s Next?

Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) fell 18% during mid-day trading on Thursday . The company traded as low as $36.86 and last traded at $32.6360. 511,437 shares changed hands during trading, a decline of 75% from the average session volume of 2,045,150 shares. The stock had previously closed at $39.82.

More Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Neutral Sentiment: Multiple temporary trading halts (LULD pauses) occurred this morning as volatility spiked; these are market‑mechanism pauses, not company announcements.
• Neutral Sentiment: Corcept plans to report Q4 and full‑year 2025 results and hold a corporate update and conference call on Feb. 24 — this event could provide management’s view on Korlym revenue risk, relacorilant strategy and legal contingencies. Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results
• Neutral Sentiment: Short‑interest data in the feed appear anomalous (reported as zero); ignore for position sizing until broker/clearing data are confirmed.
• Negative Sentiment: An appeals court affirmed that Teva’s proposed generic does not infringe two Korlym‑related patents, effectively clearing Teva to pursue a generic launch — this is the primary immediate catalyst for the selloff because it threatens Korlym revenue. Corcept Therapeutics Stock Plunges As Court Clears Teva Generic
• Negative Sentiment: Market coverage and headlines are amplifying the move; analysts/news sites report the stock “crashing” after the patent defeat, which can accelerate selling and volatility. Corcept Therapeutics Stock Crashes 21% after Patent Defeat to Teva
• Negative Sentiment: Corcept is already dealing with an FDA Complete Response Letter for relacorilant; valuation and investor reactions to that CRL remain relevant and magnify downside risk as a late product‑pipeline setback. A Look At Corcept Therapeutics (CORT) Valuation After FDA Complete Response Letter For Relacorilant
• Negative Sentiment: Separately, Kaplan Fox has alerted investors about a securities‑law probe into Corcept; ongoing investigations increase legal and disclosure risk and can sustain selling pressure until resolved. CORCEPT THERAPEUTICS ALERT: Corcept Therapeutics, Inc. (CORT) are Encouraged to Contact Kaplan Fox

Analyst Upgrades and Downgrades

Several equities analysts have commented on CORT shares. Zacks Research cut shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. HC Wainwright boosted their price target on shares of Corcept Therapeutics from $90.00 to $105.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. Canaccord Genuity Group increased their price target on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, January 23rd. UBS Group started coverage on shares of Corcept Therapeutics in a report on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 price target on the stock. Finally, Truist Financial set a $50.00 target price on shares of Corcept Therapeutics in a research note on Wednesday, December 31st. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $83.50.

Corcept Therapeutics Price Performance

The stock has a market capitalization of $3.53 billion, a PE ratio of 38.36 and a beta of 0.25. The business’s 50-day moving average price is $51.26 and its 200 day moving average price is $67.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.07 and a current ratio of 3.14.

Insiders Place Their Bets

In other news, insider William Guyer sold 20,000 shares of the stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $40.87, for a total value of $817,400.00. Following the transaction, the insider owned 1,235 shares of the company’s stock, valued at $50,474.45. This represents a 94.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Joseph Douglas Lyon sold 5,000 shares of the firm’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $79.53, for a total transaction of $397,650.00. Following the sale, the insider owned 10,277 shares in the company, valued at approximately $817,329.81. This trade represents a 32.73% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 129,500 shares of company stock worth $8,665,500. 20.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Corcept Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada raised its position in shares of Corcept Therapeutics by 18.9% in the 1st quarter. Royal Bank of Canada now owns 15,385 shares of the biotechnology company’s stock worth $1,757,000 after acquiring an additional 2,444 shares in the last quarter. Amundi bought a new position in Corcept Therapeutics in the first quarter worth $450,000. NewEdge Advisors LLC bought a new position in Corcept Therapeutics in the first quarter worth $518,000. Sequoia Financial Advisors LLC lifted its position in Corcept Therapeutics by 8.6% during the second quarter. Sequoia Financial Advisors LLC now owns 3,650 shares of the biotechnology company’s stock valued at $268,000 after buying an additional 288 shares during the period. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Corcept Therapeutics during the 2nd quarter valued at $1,217,000. Hedge funds and other institutional investors own 93.61% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.